SEARCH:
OxySure (OXYS) Appoints Christopher Kaplan to Its Strategic Advisory Board
Published Tuesday, October 06, 2015 by Hylton Dudley
OxySure Systems Inc. (OTCQB: OXYS), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other innovative medical solutions, recently announced the appointment of Christopher Kaplan to its Strategic Advisory Board. With more than 12 years of experience at Novartis in the U.S. and Europe, Mr. Kaplan brings a wealth of experience to the company as it makes its transition to the next stage of its corporate life.

The appointment of Mr. Kaplan follows the appointment of Dr. Joseph M. Chalil to the Strategic Advisory Board in late-September. Dr. Chalil is a physician and executive at Boehringer Ingelheim, the world’s largest privately held pharmaceutical company in Germany. He’s also an expert in U.S. healthcare policy and a strong advocate for patient centered care, as well as a past advisor to various national political campaigns on healthcare issues.

With an upcoming NASDAQ up-listing and new board additions, investors may want to take a closer look at the stock.

Read the entire press release here:

OxySure Systems, Inc. (OTCQB: OXYS) (“OxySure,” or the “Company”), a global leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its “oxygen from powder” technology and other innovative medical solutions, today announced that it has appointed Christopher Kaplan to its Strategic Advisory Board.

Mr. Kaplan is currently President of Cajetan, LLC, an independent healthcare consulting firm working with companies to deliver better value for patients, fuel innovation, enhance the impact and execution of marketing and sales initiatives, and reduce the cost and complexity of operating systems.

Prior to Cajetan, Mr. Kaplan spent two years with Boehringer Ingelheim as Senior Vice President and Chief Marketing Officer. That followed 12 years at Novartis in both the US and Europe. Mr. Kaplan began at Novartis as Global Head of the Cardiovascular and Metabolic Business Franchise in Basel Switzerland, then moved to Head the Nordic Region Cluster and General Manager in Stockholm Sweden, and then became Head of Northern and Central Europe and Region Europe Marketing & Sales back in Basel. He returned to the US as President, Cardiovascular & Metabolic Operating Unit, in E. Hanover New Jersey, and then served as President and General Manager of the East Operating Unit, also in E. Hanover.

Mr. Kaplan started his pharmaceutical career at Bristol-Myers Squibb Company. He moved quickly through various roles in US sales and sales management and then in US marketing. He began his international experience in Paris as the Cardiovascular Marketing Director for Europe and then progressed to his last role at Bristol-Myers Squibb as Marketing and Sales Director in Rome, Italy.

Mr. Kaplan is a graduate of Columbia University, holds a Masters of Science Degree from the University of Pennsylvania, and undertook post-graduate studies at INSEAD, Fontainebleu, France. He has also completed executive education programs at Harvard, Wharton and the London Business School.

Julian T. Ross, CEO of OxySure said, "We are continuing our plan to forward-structure our Strategic Advisory Board to strengthen our collective expertise in healthcare marketing, sales and business development. Chris has a formidable resume and proven track record of success in pharmaceutical and medical sales and marketing. His experience in international business is clearly going to be an asset to OxySure as we continue our international expansion, especially in Europe. His depth and breadth of experience in healthcare sales and marketing and his dedication to healthcare innovation will significantly enhance OxySure’s ability to access the significant opportunities available to it."

Mr. Kaplan said, "I am very pleased to be joining the OxySure Strategic Advisory Board at this inflection point in the Company's growth and history. I am impressed with the achievements OxySure has made so far and I am excited to contribute to new successes going forward."

The current list of Strategic Advisory Board members is located here: http://oxysure.com/aed/index.php/strategic-advisory-board

About OxySure Systems, Inc.

OxySure Systems, Inc. (OXYS) is a medical technology company that focuses on the design, manufacture and distribution of specialty respiratory and medical solutions. The company pioneered a safe and easy to use solution to produce medically pure (USP) oxygen from inert powders. The company owns numerous issued patents and patents pending on this technology which makes the provision of emergency oxygen safer, more accessible and easier to use than traditional oxygen provision systems. OxySure's products improve access to emergency oxygen that affects the survival, recovery and safety of individuals in several areas of need: (1) Public and private places and settings where medical emergencies can occur; (2) Individuals at risk for cardiac, respiratory or general medical distress needing immediate help prior to emergency medical care arrival; and (3) Those requiring immediate protection and escape from exposure situations or oxygen-deficient situations in industrial, mining, military, or other "Immediately Dangerous to Life or Health" (IDLH) environments. In addition to oxygen products for public/lay responder usage, OxySure also markets emergency medical solutions including AEDs (Cardiac Science, Philips, Zoll, Physio Control, Defibtech, and HeartSine), Quickclot Bleeding Control solutions, resuscitation products and pulse oximetry products. www.OxySure.com

Sign Up for Free Email Alerts on OxySure Systems, Inc. (OXYS)
  • Press Releases
  • In-Depth Articles
  • SEC Filing Alerts
  • Presentation Schedules
  • Trading Alerts
First Name:
Last Name:
Email:
More OXYS Coverage
OxySure (OXYS) Provides Updates on FDA Letter
OxySure Therapeutics (OXYS) May Be Undervalued Compared to Others in Biotech Space
BUYINS.NET Anticipates Short Squeeze for Oversold OxySure (OXYS)
OxySure Launches Cardiac Safety eCommerce Store
OxySure Launches 'March Madness' Sales Competition
OxySure (OXYS) Ramps Up Production as Growth Continues
OxySure Secures Economic Incentives from City of Frisco
OxySure Doubles Production Capacity to Fill Backlog
OxySure Adds Depth in Medical Supply Capability With New Agreement
OxySure (OXYS) Targets Sports Industry at the Innovations Investor Conference
OxySure Expands Sales Team with Florida Manager
OxySure (OXYS) Partners to Provide Easy, Fast, & Flexible Financing Options
3 Stocks Tackling Concussion Issues in Pro Athletes
OxySure Therapeutics (OXYS) Adds Former Ivax Director to Advisory Board
OxySure Expands Awareness at JP Morgan Healthcare Conference